<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00428168</url>
  </required_header>
  <id_info>
    <org_study_id>BET202</org_study_id>
    <nct_id>NCT00428168</nct_id>
  </id_info>
  <brief_title>Study to Examine the Effect of Betahistine on Body Weight Gain Due to Olanzapine Treatment</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Examine the Effect of Betahistine on Body Weight Gain Due to Olanzapine Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OBEcure Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>OBEcure Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, multicenter, multinational study.&#xD;
      Approximately 78 subjects (39 per treatment group) will be randomized into this 16 week&#xD;
      study.&#xD;
&#xD;
      A screening visit will be used to determine subject suitability for inclusion in the trial.&#xD;
&#xD;
      Within 7 days of the screening visit, subjects who meet all inclusion criteria and none of&#xD;
      the exclusion criteria will be randomly assigned to 1 of the following 2 treatment groups:&#xD;
&#xD;
        -  Olanzapine OD plus betahistine 24 mg BID (48 mg/day total),&#xD;
&#xD;
        -  Olanzapine OD plus matching placebo BID.&#xD;
&#xD;
      Double-blind treatment will continue for 16 weeks. During this period, olanzapine dosage will&#xD;
      be determined according to the discretion of the treating physician. In addition, 5 study&#xD;
      visits (at 2, 4, 8, 12, and 16 weeks) will take place. Study medication (betahistine or&#xD;
      matching placebo) will be administered BID (in the morning and together with olanzapine in&#xD;
      the evening).&#xD;
&#xD;
      The primary statistical hypothesis to be tested is that the mean change from Baseline to Week&#xD;
      16 will be different between the treatment and placebo groups&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Interim Analysis result indicated the study will not show a significant benefit of the study&#xD;
    medication on the primary endpoint.&#xD;
  </why_stopped>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change in body weight from Baseline to Week 16</measure>
    <time_frame>Week 16</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of weight change</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in waist circumference from Baseline to Week 16</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from Baseline to Week 16 in measurements of obesity associated cardiovascular risk factors: sitting systolic and diastolic blood pressure, plasma lipid profile (LDL, non-HDL-C, TG, TC, and HDL-C), HbA1c, and FPG</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the pharmacokinetic properties of olanzapine due to betahistine co-administration</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in psychiatric condition since randomization</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Weight Gain</condition>
  <arm_group>
    <arm_group_label>Betahistine 24 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Betahistine</intervention_name>
    <description>Betahistine 24mg BID</description>
    <arm_group_label>Betahistine 24 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject (or legal guardian) is capable and willing to provide signed written informed&#xD;
             consent;&#xD;
&#xD;
          -  Male or female subjects 16 to 45 years of age;&#xD;
&#xD;
          -  Body mass index in the range of 18.5 to 35 kg/m2;&#xD;
&#xD;
          -  Diagnosed as having schizophrenia, schizoaffective disorder, schizophreniform disorder&#xD;
             or a psychosis disorder that is not otherwise specified (NOS) according to the DSM-IV&#xD;
             criteria;&#xD;
&#xD;
          -  Maximum of 6 weeks cumulative lifetime exposure to risperidone, OR maximum of 3 weeks&#xD;
             cumulative lifetime exposure to any other antipsychotic medication;&#xD;
&#xD;
          -  Designated by the managing physician to be appropriate for treatment with olanzapine;&#xD;
             and&#xD;
&#xD;
          -  If female: is non-lactating, has a negative blood serum pregnancy test result, and&#xD;
             does not plan on becoming pregnant during the study, or is not of childbearing&#xD;
             potential (hysterectomy or tubal ligation at least 6 months prior to randomization or&#xD;
             post-menopausal for 1 year); if of childbearing potential (including peri-menopausal&#xD;
             women who have had a menstrual period within one year), must practice and be willing&#xD;
             to continue to practice appropriate birth control (such as implants, injectables, oral&#xD;
             contraceptives, intrauterine contraceptive devices, sexual abstinence, tubal ligation,&#xD;
             or a vasectomized partner) during the entire study duration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has obesity of known endocrine origin (e.g., Cushing's disease, Addison's disease,&#xD;
             hypothalamic tumor);&#xD;
&#xD;
          -  Has a medical history (e.g., morbid childhood obesity) and/or physical characteristics&#xD;
             (e.g., polydactyly) suggestive of genetic obesity (e.g., ob/ob genotype) or&#xD;
             syndromatic obesity (e.g., Prader-Willi syndrome, Bardet Biedl syndrome);&#xD;
&#xD;
          -  Previous surgical procedures for weight loss;&#xD;
&#xD;
          -  Has had liposuction within 1 year before screening or is planning to have liposuction&#xD;
             during the study;&#xD;
&#xD;
          -  Has a clinically significant history or presence of any of the following conditions:&#xD;
&#xD;
          -  Active or past history of cardiovascular or cerebrovascular disease including unstable&#xD;
             angina, myocardial infarction, transient ischemic attacks/stroke, clinically&#xD;
             significant arrhythmia, congestive heart failure, or cardiac valve abnormalities;&#xD;
&#xD;
          -  Type 1 diabetes mellitus;&#xD;
&#xD;
          -  Type 2 diabetes mellitus with treatment other than metformin monotherapy and/or diet&#xD;
             with HbA1c &gt;8%;&#xD;
&#xD;
          -  Severe type 2 diabetes with history of ketoacidosis or diabetic ulcers, or presence of&#xD;
             retinopathy, neuropathy, or nephropathy;&#xD;
&#xD;
          -  Renal insufficiency defined as a serum creatinine &gt;=1.5 mg/dL (133 µmol/L) at&#xD;
             screening;&#xD;
&#xD;
          -  Malignant disease, other than basal cell carcinoma, within 5 years of screening;&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) &gt;2 x ULN;&#xD;
&#xD;
          -  Thyroid-stimulating hormone (TSH) outside of the normal range;&#xD;
&#xD;
          -  Plans on having any surgery (elective or otherwise) during the course of the study;&#xD;
&#xD;
          -  Has uncontrolled hypertension (sitting blood pressure &gt;160/95 mmHg at screening or&#xD;
             randomization), uncontrolled hyperlipidemia (triglycerides [TG] &gt;=400 mg/dL or&#xD;
             low-density lipoprotein cholesterol [LDL] &gt;160 mg/dL), or uncontrolled diabetes (HbA1c&#xD;
             &gt;8%);&#xD;
&#xD;
          -  Diagnosis of asthma;&#xD;
&#xD;
          -  History of peptic ulcers;&#xD;
&#xD;
          -  History of HIV;&#xD;
&#xD;
          -  Has a physical examination or electrocardiogram (ECG) with significant abnormalities,&#xD;
             as judged by the investigator;&#xD;
&#xD;
          -  Chronic antihistamine use or use of antihistamines within 14 days of randomization;&#xD;
&#xD;
          -  History of pheochromocytoma&#xD;
&#xD;
          -  Requires treatment with any of the following medications but has not been on a stable&#xD;
             treatment regimen for a minimum of 90 days prior to screening:&#xD;
&#xD;
          -  Hormone replacement therapy;&#xD;
&#xD;
          -  Oral contraceptives;&#xD;
&#xD;
          -  Antihypertensive agents;&#xD;
&#xD;
          -  Metformin;&#xD;
&#xD;
          -  Lipid-lowering agents; or&#xD;
&#xD;
          -  Thyroid replacement therapy;&#xD;
&#xD;
          -  Has been treated over the past 60 days, is currently treated, or is expected to&#xD;
             require or undergo treatment with any of the following excluded medications;&#xD;
&#xD;
          -  All prescription or over-the-counter agents taken for the purpose of weight reduction,&#xD;
             including (but not limited to) the following anti obesity agents:&#xD;
&#xD;
          -  Prescription drugs such as orlistat (Xenical), sibutramine (Meridia), and phentermine&#xD;
             (Adipex-P, Celltech, Pro-Fast SA, Pro-Fast SR, Fastin, Oby trim, Zantryl, Teramine,&#xD;
             Phentride, Phentercot, Obephen, Oby-cap); or&#xD;
&#xD;
          -  Over-the-counter antiobesity agents (e.g., herbal supplements or other alternative&#xD;
             remedies such as Cortislim, Dexatrim, Acutrim);&#xD;
&#xD;
          -  Systemic steroids administered by oral, intravenous, or intramuscular route;&#xD;
&#xD;
          -  Drugs that directly affect gastrointestinal motility (e.g., Reglan® and Propulsid®,&#xD;
             and chronic [taken for more than 10 days within a 6-month period] macrolide&#xD;
             antibiotics such as erythromycin and newer derivatives);&#xD;
&#xD;
          -  Anti-depressants or benzodiazepines unless one of the following permitted drugs:&#xD;
             escitalopram (Cipralex®), citalopram (Celexa®), clonazepam (Clonapam®), alprazolam&#xD;
             (Xanax®), chlordiazepoxide (Librium®), diazepam (Valium®) and lorazepam (Ativan®);&#xD;
&#xD;
          -  Calcitonin (e.g., Miacalcin®);&#xD;
&#xD;
          -  Insulin;&#xD;
&#xD;
          -  Exenatide (Byeta®);&#xD;
&#xD;
          -  Sulfonylureas (e.g., Diamicron®, Amaryl®, Glucotrol®, Micronase®); or&#xD;
&#xD;
          -  Meglitinides (e.g., Starlix®, Prandin®);&#xD;
&#xD;
          -  Receipt of any investigational treatment (drug or device) within 90 days prior to&#xD;
             screening; or&#xD;
&#xD;
          -  Is an immediate family member of personnel directly affiliated with the study at the&#xD;
             investigative sites, or is personally directly affiliated with the study at the&#xD;
             investigative sites.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yaffa Beck</last_name>
    <role>Study Chair</role>
    <affiliation>OBEcure Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Capital Health, Edmonton Mental Health Clinic</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5K 2J5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Alexander McIntyre</name>
      <address>
        <city>Penticton</city>
        <state>British Columbia</state>
        <zip>V2A 4M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vancouver Island Health Authority</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8R 4Z3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Ivan Kowalchuk</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3K 2E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capital District Health Authority</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen's University</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 5G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Douglas Hospital Research Centre</name>
      <address>
        <city>Verdun (Montreal)</city>
        <state>Quebec</state>
        <zip>H4H 1R3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abarbanel Hospital</name>
      <address>
        <city>Bat Yam</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geha Psychiatric Hospital</name>
      <address>
        <city>Petach Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lev Hasharon</name>
      <address>
        <city>Tirat Hacarmel</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Israel</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <study_first_submitted>January 25, 2007</study_first_submitted>
  <study_first_submitted_qc>January 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2007</study_first_posted>
  <last_update_submitted>October 13, 2015</last_update_submitted>
  <last_update_submitted_qc>October 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Betahistine</keyword>
  <keyword>Weight Gain Control</keyword>
  <keyword>Weight Gain due to Olanzapine Treatment</keyword>
  <keyword>Obesity</keyword>
  <keyword>Schizophrenic disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Body Weight</mesh_term>
    <mesh_term>Weight Gain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Betahistine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

